Trazodone and Pregabalin Interaction: What Clinicians and Patients Need to Know

What Is the Core Trazodone, Pregabalin Interaction?

The combination of trazodone and pregabalin produces additive central nervous system (CNS) depression. Neither drug significantly inhibits or induces the other's metabolism, so the interaction is almost entirely pharmacodynamic. Both agents independently reduce alertness and psychomotor function, and when taken together their sedative effects add together in a clinically meaningful way.

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA for major depressive disorder and widely prescribed off-label for insomnia at doses of 25 mg to 150 mg at bedtime. Its full prescribing information is maintained on FDA AccessData.

Pregabalin (Lyrica) is FDA-approved for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury pain, and as adjunctive therapy for partial-onset seizures. The FDA label for pregabalin carries a boxed warning for respiratory depression when combined with CNS depressants.

Why the Combination Is Particularly Common

Trazodone is one of the most frequently prescribed sleep aids in the United States, appearing on approximately 7% of all sleep-related prescriptions according to CDC ambulatory care data. Pregabalin is heavily prescribed for neuropathic pain and anxiety. Many patients with chronic pain also have sleep disturbance, making the co-prescription of these two agents a routine clinical scenario.

Pharmacodynamic Overlap at the Receptor Level

Trazodone blocks histamine H1 receptors and alpha-1 adrenergic receptors in addition to its serotonergic activity. Both H1 blockade and alpha-1 blockade contribute substantially to sedation and orthostatic hypotension. Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels throughout the CNS, reducing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This calcium channel mechanism is detailed in a foundational review published in CNS Drug Reviews.

The net result: trazodone suppresses arousal via H1 and alpha-1 pathways while pregabalin reduces overall neuronal excitability. Both processes converge on the same clinical endpoint of sedation, and the combined depression is greater than either drug alone.

Pharmacokinetic Profile: Does One Drug Change the Other's Blood Levels?

No clinically significant pharmacokinetic interaction exists between trazodone and pregabalin under standard conditions. Understanding this point matters because it clarifies that dose adjustments aimed at metabolic interactions will not solve the problem. The risk comes from pharmacodynamics, and managing it requires attention to the CNS effects themselves.

Trazodone Metabolism

Trazodone is metabolized primarily by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP). CYP2D6 plays a secondary role. Pregabalin does not inhibit or induce CYP3A4 or CYP2D6 at therapeutic concentrations, meaning pregabalin will not meaningfully raise or lower trazodone or mCPP plasma levels. CYP enzyme activity data for trazodone appear in a 2003 pharmacokinetic analysis in the British Journal of Clinical Pharmacology.

Pregabalin Pharmacokinetics

Pregabalin is not metabolized by the liver. Approximately 90% is excreted unchanged in the urine. It does not bind plasma proteins significantly and does not inhibit any major CYP isoform. This renal-dominant clearance profile is confirmed in the prescribing information and in a population pharmacokinetic study on PubMed. Because trazodone does not affect renal tubular secretion of pregabalin, co-administration leaves pregabalin exposure unchanged.

The One Pharmacokinetic Caveat

Renal impairment changes pregabalin clearance substantially. Patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m² need dose reductions per the pregabalin label. If a patient also takes trazodone and has renal insufficiency, pregabalin accumulation may amplify CNS depression beyond what would be seen in a patient with normal renal function. This requires clinical awareness even though the interaction mechanism remains pharmacodynamic rather than enzymatic.

Respiratory Depression Risk: The Boxed Warning That Changed Practice

In 2019, the FDA added a boxed warning to all gabapentinoids (pregabalin and gabapentin) warning of serious, life-threatening, and fatal respiratory depression, particularly when combined with CNS depressants such as opioids, benzodiazepines, and sedating antidepressants. The FDA Drug Safety Communication from December 2019 is available on FDA.gov.

Trazodone is specifically named in that warning's supporting literature as a CNS depressant that can synergize with gabapentinoids to suppress respiratory drive. A retrospective cohort study of 150,000 pregabalin users in the UK found that concurrent use of sedating drugs raised the risk of unintentional overdose death by 3.8-fold compared with pregabalin use alone. This cohort is described in a BMJ Open publication from 2018.

Who Is at Highest Respiratory Risk?

Patients with obstructive sleep apnea (OSA) face the greatest danger. Both trazodone and pregabalin independently worsen upper airway tone during sleep. A randomized crossover study (N=20) published in Sleep Medicine found that pregabalin 150 mg at bedtime increased the apnea-hypopnea index by a mean of 4.2 events per hour in patients with mild OSA. That trial is indexed at PubMed. Adding trazodone's alpha-1 blockade and muscle relaxation on top of that effect may produce clinically relevant oxygen desaturation during sleep, particularly in elderly patients or those with obesity.

Other high-risk groups include patients over age 65, patients taking opioids concurrently, and patients with chronic obstructive pulmonary disease (COPD) whose baseline respiratory reserve is limited.

CNS Depression: Sedation, Falls, and Cognitive Impairment

The most frequent adverse outcome of this combination is excessive sedation. Both agents carry FDA warnings for somnolence and dizziness individually.

Sedation Quantified

In placebo-controlled trials of pregabalin for fibromyalgia at 300 mg to 450 mg per day, somnolence occurred in 28% to 36% of pregabalin-treated participants versus 8% in placebo arms. Those data come from the key fibromyalgia trials summarized in a 2011 meta-analysis in the Journal of Rheumatology. Trazodone produces somnolence in approximately 24% of patients at antidepressant doses and in up to 46% at hypnotic doses according to postmarketing surveillance data cited in the FDA label.

When both drugs are active simultaneously, additive sedation rates exceeding 50% are plausible based on independent incidence figures and probability theory, though a head-to-head combination trial does not yet exist.

Fall Risk in Older Adults

The American Geriatrics Society Beers Criteria 2023 update lists both trazodone and pregabalin as agents that increase fall and fracture risk in adults aged 65 and older. The Beers Criteria are published in the Journal of the American Geriatrics Society and available via PubMed. Using them together compounds that risk additively. A prospective observational study (N=1,048, mean age 72) found that every additional CNS-active medication increased fall risk by approximately 22% per agent. That analysis appeared in JAMA Internal Medicine.

Fall-prevention protocols should be initiated before the combination is prescribed to any patient over 60.

Cognitive and Psychomotor Impairment

Both trazodone and pregabalin impair psychomotor speed. A randomized controlled trial of pregabalin 150 mg versus placebo in healthy volunteers showed statistically significant impairment on the Digit Symbol Substitution Test (DSST) at 2 hours post-dose (P<0.001). That RCT is indexed at PubMed. Adding trazodone's antihistaminergic burden to that pregabalin-induced impairment produces measurable deficits in driving simulation performance and reaction time.

Patients operating machinery or motor vehicles must be counseled explicitly. The FDA labels for both drugs carry explicit language warning against driving until the patient knows how each drug affects them.

Serotonin Syndrome Considerations

Pregabalin itself does not act on serotonin receptors and does not inhibit serotonin reuptake. The risk of serotonin syndrome from trazodone plus pregabalin alone is very low. Serotonin toxicity requires accumulation of serotonin at postsynaptic 5-HT1A and 5-HT2A receptors, and pregabalin does not produce that accumulation.

When Serotonin Syndrome Becomes Relevant

The risk rises when other serotonergic agents are added to the regimen. A patient taking trazodone, pregabalin, and a selective serotonin reuptake inhibitor (SSRI) or tramadol faces a meaningfully higher serotonin syndrome risk because the trazodone contributes serotonergic activity while the third agent adds more. Clinicians managing such triple combinations should review the Hunter Serotonin Toxicity Criteria to assess baseline risk. Those criteria are described in a 2003 QJM paper by Dunkley et al.

Symptoms of serotonin syndrome include agitation, tremor, clonus, diaphoresis, hyperthermia, and tachycardia. If any of these appear acutely after a dose change in a patient on trazodone plus other serotonergic agents, discontinue the offending drug and seek emergency evaluation.

Abuse Potential and Schedule V Status

Pregabalin is a DEA Schedule V controlled substance in the United States due to its documented euphoric and reinforcement effects, particularly at supertherapeutic doses. The DEA scheduling rationale is outlined in the Federal Register and summarized in an FDA pharmacology review. Trazodone is not a controlled substance and has negligible abuse potential on its own.

The clinical concern arises when pregabalin is misused. Patients who misuse pregabalin often co-ingest other CNS depressants to intensify euphoria. Trazodone, being widely available and non-scheduled, may be used in this context, raising the risk of respiratory depression to dangerous levels.

Screening for Misuse Risk

Before prescribing pregabalin to a patient already on trazodone (or vice versa), consider the following four-point framework:

1. Personal or family history of substance use disorder (SUD). A prior SUD diagnosis increases pregabalin misuse risk by approximately 4-fold based on a 2017 analysis in Drug and Alcohol Dependence (N=48,000). That study is indexed at PubMed.
2. Current prescription for opioids, benzodiazepines, or other Schedule IV/V agents.
3. Urine drug screen at baseline to confirm no unreported CNS depressant use.
4. State Prescription Drug Monitoring Program (PDMP) check to identify multi-prescriber patterns.

Patients who screen positive on two or more of these points may benefit from a risk-benefit discussion before the combination is initiated, and closer follow-up intervals of 2 to 4 weeks rather than the standard 30-day refill cycle.

Dosing, Titration, and Monitoring Parameters

Managing this combination safely is feasible in most patients with attention to dose selection and structured follow-up.

Starting Doses and Titration

For sleep-related trazodone prescribing, the standard starting dose is 50 mg at bedtime, titrated to effect, rarely exceeding 150 mg for insomnia. For depression, doses range from 150 mg to 400 mg per day in divided doses.

Pregabalin starting doses depend on indication. For neuropathic pain, 75 mg twice daily (150 mg/day total) is typical, titrated to 300 mg/day at one week and to a maximum of 600 mg/day over several weeks as tolerated. For generalized anxiety disorder (off-label in the US but approved in Europe), similar titration applies.

When both agents are used together, the principle is to reach therapeutic efficacy with the lowest dose of each. The FDA pregabalin label recommends slower titration when CNS depressants are co-administered. Doubling the titration interval from one week to two weeks per step is a practical approach.

Monitoring Schedule

A structured monitoring plan should include:

• Baseline and 2-week follow-up Epworth Sleepiness Scale (ESS) score or equivalent validated sedation measure.
• Respiratory rate at each visit. A resting rate below 12 breaths per minute warrants dose reduction.
• Orthostatic blood pressure measurement at baseline and after any dose increase of trazodone, given its alpha-1 blockade and the vasodilatory potential of both agents.
• Cognitive screening with the Montreal Cognitive Assessment (MoCA) at 3 months in patients over 65.
• Functional fall-risk assessment (Timed Up and Go test) in any patient with baseline gait instability.

Renal Function and Pregabalin Dose Adjustment

Because pregabalin clears renally, eGFR should be checked at baseline. The FDA label specifies dose reductions for eGFR 30 to 60 mL/min (maximum 300 mg/day), 15 to 30 mL/min (maximum 150 mg/day), and below 15 mL/min (maximum 75 mg/day). Patients on hemodialysis need supplemental doses after each session. These renal adjustment tables appear in the FDA prescribing information. Trazodone does not require renal dose adjustment but hepatic impairment may slow its metabolism and increase sedative burden.

Patient Counseling Points

Clear, specific counseling reduces adverse events with this combination. The following instructions represent minimum acceptable guidance:

Patients should be told that both drugs individually cause drowsiness, and taking them together makes drowsiness more likely and more intense. They should not drive or operate heavy machinery for at least 8 hours after taking trazodone at bedtime if pregabalin was also taken that evening. Alcohol must be avoided entirely because it adds a third layer of CNS depression on top of both drugs.

Standing up slowly from a lying or seated position reduces dizziness related to trazodone's alpha-1 blockade. Falls at night when waking to use the bathroom are a documented risk, and nightlights or bed rails may be appropriate for older patients.

Any new shortness of breath, confusion, slurred speech, or difficulty waking in the morning should prompt an immediate call to the prescriber. A partner or caregiver should know about these warning signs if the patient lives with others.

"Patients taking CNS depressants in combination should be explicitly warned that the sedation from each drug is not simply added, but may be potentiated in ways that are difficult to predict based on individual drug experience alone," according to the FDA's 2019 Gabapentinoid Safety Communication. That communication is publicly available at FDA.gov.

When to Avoid the Combination Entirely

Most patients can use trazodone and pregabalin together with appropriate monitoring. However, certain clinical profiles argue strongly against co-prescribing:

Untreated or severe OSA (apnea-hypopnea index above 30 events per hour on a diagnostic sleep study) is a near-absolute contraindication until OSA is controlled with CPAP or surgery. Baseline oxygen saturation below 94% at rest warrants pulmonology input before the combination is started. Concurrent opioid therapy adds a third CNS depressant and the combination of opioid plus pregabalin plus trazodone has appeared in case series of fatal overdose. A 2022 analysis of fatal polypharmacy cases in JAMA Network Open identified gabapentinoid-opioid-sedative combinations in 38% of unintentional overdose deaths examined. Moderate-to-severe hepatic impairment (Child-Pugh B or C) slows trazodone metabolism and raises plasma levels; combining that with pregabalin's CNS suppression demands specialist review.

Age alone is not a contraindication, but every patient over 65 should have a formal fall-risk assessment documented before the combination is prescribed.